AstraZeneca Concentrates Biologics At MedImmune, Ups R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.
You may also be interested in...
Tie-Up With MedImmune Marks Catalyst's Second Partnership Deal In A Week
The collaboration involves discovery work on undisclosed targets in the autoimmune and inflammatory disease areas.
Tie-Up With MedImmune Marks Catalyst's Second Partnership Deal In A Week
The collaboration involves discovery work on undisclosed targets in the autoimmune and inflammatory disease areas.
MedImmune Appoints Development Leadership Team
Former Cambridge Antibody Technology exec to oversee product development.